Benefits
Studied for breast health during breastfeeding
In lactating women, one manufacturer-sponsored randomized trial (625 enrolled, 291 completing the 16 week course) reported a lower incidence rate of clinical mastitis in the probiotic group (18 episodes versus 40, rate 0.130 versus 0.263). An independent 2017 European Food Safety Authority review concluded the cause and effect relationship was not established. This is a clinical outcome studied in nursing women, not a general benefit.
Studied against antibiotics in lactating women
In one open-label trial (352 lactating women) that was not placebo-controlled, women taking this strain for 3 weeks improved similarly to women given antibiotics. It was an unblinded comparison in women already under medical care for a breast infection, not evidence that a supplement should replace medical treatment.
Reduced breast pain during lactation
In manufacturer-run trials of lactating women with painful breastfeeding, this strain was associated with lower breast pain scores versus placebo. The finding comes from a narrow clinical group under care, not from general use.
Studied in infant formula (a separate population)
In infant formula trials, this strain was linked to fewer gastrointestinal infections in babies. That evidence is in infants fed a supplemented formula, a different population that does not transfer to an adult taking a capsule. The cited safety trial measured gastrointestinal infections, not respiratory ones.
Originally isolated from human milk
The strain was originally isolated from healthy breast milk. It has a good safety record in trials of lactating women and infants. A proposed European health claim for reducing mastitis risk was reviewed and rejected in 2017.
Antimicrobial peptide production
In laboratory tests, this strain produces compounds active against Staphylococcus bacteria. This is a proposed mechanism observed in vitro, not a demonstrated clinical benefit.
Mechanism of action
Mammary microbiota niche specialization (breast milk origin)
Originally isolated from healthy breast milk — the strain is naturally adapted to the mammary environment. Niche specialization is the proposed basis for selective benefit at this site vs other Lactobacillus strains isolated from gut or vaginal sources.
Staphylococcus competitive exclusion
Trial data reported significantly lower Staphylococcus spp. load in breast milk of the probiotic group. Staphylococcus is the main causal agent of mastitis. Competitive exclusion via niche occupation, antimicrobial peptide production, and lactic acid / low-pH maintenance are the proposed mechanisms.
Antimicrobial peptide production
Bacteriocin-like substances active against Staphylococcus species are produced by L. fermentum CECT5716 in vitro. This is a foundational mechanism for the Staphylococcus-load reduction observed clinically.
Lactic acid and low-pH maintenance
Lactobacillus species produce lactic acid lowering local pH — a foundational antimicrobial mechanism that disadvantages alkaline-tolerant pathogens including some Staphylococcus species.
Mammary microbiota dysbiosis correction
Painful breastfeeding and mastitis are associated with dysbiosis of the mammary microbiota — Staphylococcus overgrowth at the expense of normal commensals. Restoring commensal balance is the proposed broader mechanism beyond direct Staphylococcus suppression.
Clinical trials
Clinical evidence on Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®) for the indications and outcomes described.
625 women
Hurtado JA et al. 2017, Breastfeeding Medicine, NCT02203877, PROLAC Group multicenter investigation. Randomized double-blind placebo-controlled multicenter trial in 625 women (291 completed 16-week treatment) recruited 1-6 days post-childbirth. Probiotic: 3×10⁹ CFU/day L. fermentum CECT5716 vs maltodextrin placebo for 16 weeks. Clinical mastitis incidence rate 0.130 (probiotic) vs 0.263 (control), p=0.021 — 51% reduction. Staphylococcus load in breast milk was lower in the probiotic group. Authored by staff of the strain's manufacturer; an independent 2017 European Food Safety Authority review found the cause and effect relationship for reducing mastitis risk was not established.
4-arm dose-ranging trial (3×10⁹, 6×10⁹, 9×10⁹ CFU/day, plus placebo) for 3 weeks in women with painful breastfeeding.
Clinical population described in trial publication.
4-arm dose-ranging trial (3×10⁹, 6×10⁹, 9×10⁹ CFU/day, plus placebo) for 3 weeks in women with painful breastfeeding. Compared with baseline, Staphylococcus counts fell within the probiotic groups while the placebo group stayed similar, and breast pain scores were lower in the probiotic groups. No dose-response was seen: the three doses behaved alike. This is a manufacturer-run trial in lactating women with painful breastfeeding (Maldonado-Lobon 2015).
Clinical evidence on Lactobacillus fermentum CECT5716 (Lc40 / Hereditum®) for the indications and outcomes described.
Clinical population described in trial publication.
Bond DM, Morris JM, Nassar N. 2017, BMC Pregnancy and Childbirth, PMID 28525984. This is a published study protocol only (the APProve trial, planning 600 women), describing a design to test whether a probiotic prevents mastitis. It reports no participants and no results, so it provides no efficacy evidence.